摘要
肿瘤血管生成抑制剂是一类能破坏或抑制血管生成，有效地阻止肿瘤的生长和转移的药物。按作用机制可分为五大类：（１） 抑制基底膜降解；（２） 直接抑制内皮细胞增殖；（３） 抑制血管生长因子活化；（４） 抑制内皮细胞特异性整合素／ 生存信号；（５） 其它非特异性作用机制的药物。本文主要介绍了肿瘤血管生成抑制剂的研究现状，并对我国在肿瘤血管生成抑制剂研究方面可采取的战略进行了探讨。
Tumor angiogenesis has become the focus of intense interest as a potential target for novel cancer therapies.Tumor angiogenesis inhibitor are the drugs which can destory or inhibit neovascularization, and block the growth and metastasis of cancer. For clinical applications it may be useful to divide the antiangiogenic drugs into categories: class 1 Drugs that block matrix breakdown, class 2 Drugs that inhibit endothelial cells directly, Class 3 Drugs that block activators of angiogenesis, Class 4 Drugs that inhibit endothelial-specific integrin/survival signaling, class 5 Drugs with non-specific mechanisms of action. There are many challenges that must be met before tumor angiogenesis inhibitor can be uesd to effectively treat human tumors. This review intends to provide the recent progress of angiogenesis inhibitors at home and abroad, and discuss strategies in the development of them. Some in vitro and in vivo experimental methods most in use for evaluating antiangiogenic effects were described.
出处
《世界科技研究与发展》
CSCD
1999年第5期31-34,35,共5页
World Sci-Tech R&D
